Study 6: Benralizumab (MEDI-563) in patients with severe asthma

Principal Investigator

Dr. Parameswaran Nair

Study Title

A Multicentre, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients with Uncontrolled Asthma (CALIMA)


Asthma is associated with inflammation (swelling) of the air passages. Interleukins, proteins that are made in the body, are involved with inflammation and IL-5 appears to be involved with asthma. IL-5 is important for the survival and activation of white blood cells called eosinophils, which are involved in inflammation of the air passages. Benralizumab is an antibody made against the IL-5 receptor which prevents the IL-5 molecule affecting eosinophils. Benralizumab may help decrease inflammation in the air passages of people with asthma. Preliminary studies in people with moderate to severe asthma who have received benralizumab have shown an improvement in asthma control.


This study evaluates the efficacy of a monoclonal antibody directed against the IL5 receptor, Benralizumab, in patients with moderate to severe asthma to decrease exacerbations, improve lung function and quality of life.

For more information about this study, please contact study coordinator Melanie Kjarsgaard by e-mail at or Katherine Radford at

Accessibility for Ontarians With Disabilities Act (AODA)


The Faculty of Health Sciences is committed to providing a website that is accessible to the widest possible audience. If there is an accessibility issue with this website, please contact us at